MAP Pharma (MAPP) Misses Q4 Views by 2c
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 loss of $0.46, 2 cents worse than the analyst estimate of ($0.44).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lexmark (LXK) Gets CFIUS Approval for Apex Tech Deal
- Pepsi (PEP) Tops Q3 EPS by 8c
- Sunlink Health Systems (SSY) Reports Q4 Loss of $0.09/Share
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!